Offer a copay program for privately insured patients

Deadline not yet reached (796 days left)

Announced: 13 Oct 2023
Due: 31 Dec 2028

Deadline
Met
Late
Not met
Today

What the company said

“Beginning in 2024, Pfizer will sell Paxlovid to privately insured patients (commercial) with prices to be negotiated with payers and offer a copay program through 2028.”

SourcePfizer Inc. Form 8-K press release, 2023-10-13
FilingSEC filing index
Deadline as statedthrough 2028
Deadline used31 Dec 2028, the last day of the stated period
TypeProject
Permanent referenceKI-C-2023-PFE-004743
Cite as https://keptindex.org/c/KI-C-2023-PFE-004743/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2028.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Project other
Indicative materiality: Low rules
Action: Offer
Deliverable: Copay program for privately insured patients
Where: U.S.
Language: Firm (“will”, “on track to”)
In the company’s control: High
Specificity: High
Depends on: Customer

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Pfizer Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2023-PFE-004743 · Corrections policy